Biovie Completes Enrollment for Phase 2 Parkinson's Trial of Bezisterim
New to The Street TVJanuary 13, 20261 min57,539 views
9 connections·11 entities in this video→SUNRISE PD Trial Update
- 🎯 Biovie has successfully completed enrollment for its Phase 2 SUNRISE PD clinical trial.
- 💡 The trial is evaluating Bezisterim for the treatment of early-stage Parkinson's disease.
Patient Cohort Details
- 👥 The study enrolled 60 patients diagnosed with Parkinson's within the last four years.
- ⚠️ Participants had not yet received treatment with carbidopa or levodopa.
- 🔬 The trial aims to assess Bezisterim's effect on both motor and non-motor symptoms.
Next Steps and Timeline
- 📊 With enrollment complete, Biovie will now analyze the data.
- 📈 Top-line results from the trial are expected to be reported in the first half of this year.
Knowledge graph11 entities · 9 connections
How they connect
An interactive map of every person, idea, and reference from this conversation. Hover to trace connections, click to explore.
Hover · drag to explore
11 entities
Chapters1 moments
Key Moments
Transcript4 segments
Full Transcript
Topics11 themes
What’s Discussed
BiovieBezisterimParkinson's DiseaseSUNRISE PD TrialPhase 2 Clinical TrialNeurological DiseasesNeurodegenerative DiseasesCarbidopaLevodopaBiotech InvestingDrug Development
Smart Objects11 · 9 links
Company· 1
Products· 2
Events· 3
Person· 1
Concepts· 4